Actively Recruiting
Phase 2 Study of Long-acting Antibodies Alone and in Combinations for Adults with Moderate to Severe Ulcerative Colitis
Led by Spyre Therapeutics, Inc. · Updated on 2026-07-28
645
Participants Needed
259
Research Sites
39 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of several long-acting antibody treatments for adults with moderately to severely active ulcerative colitis UC. This Phase 2, multicenter platform study aims to compare multiple investigational therapies, including both single agents and combinations, to better understand their potential benefits and risks. The study is sponsored by Spyre Therapeutics, Inc. and involves adults aged 18 to 75 years with active UC confirmed by endoscopy and histology.
CONDITIONS
Brief Title
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Research Team
S
SKYLINE-UC Trial Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
